EDTA - The future of endoluminal protection
THIS SITE IS UNDER GOING CONSTRUCTION. THE FOLLOWING INFORMATION IS A GENERAL OVERVIEW OF OUR FIELD OF WORK.
Maintaining patency in a central venous access device is critical to managing quality care for every catheterized patient.
Device occlusions are a source of multiple risks for those patients who rely on a central venous or peripheral access devices to provide drugs, nutrition or other life-saving treatments and interventions.
Aseptica has multiple formulations in development for multiple applications.
The need to replace heparin and saline as the Standard-of-care for catheter lock/flushes has driven Aseptica's innovative discovery.
All central venous access devices (IVAD's) require a liquid solution that safely dwells inside the catheter in between 'access' events (a lock) and can be safely flushed into the patient (a lock/flush).
The safety of the EDTA lock/flush developed by Aseptica is likely to revolutionize the future of catheter lock/flush choices.
Aseptica's technology does not control, diagnose, monitor or correct a defect of the heart or of the central circulatory system. Aseptica's technology does not achieve it's intended (or Primary) mode of action by pharmocological, immunilogical or metabolic means.
Aseptica's technology does not function as a systemic treatment for any disease.
Aseptica, Inc is currently developing product supply to various countries.
In the year to come Aseptica will post more current information and links to relevant sites that will help to promote the understanding of catheter related complications and how new technologies are provideing solutions that were not imagined 10 years ago. To learn more about our company click here.